高原缺氧与肠黏膜屏障损伤研究

高原环境具有气压低、氧分压低、辐射强、寒冷、风大、湿度低、灾害天气多等特点,这种急剧变化的气候环境是导致肠黏膜损伤的关键因素。肠黏膜屏障作为机体发挥防御功能的防线之一,可以保护机体不受内源性微生物及其毒素的伤害。研究高原缺氧下肠黏膜损伤的机制,将有助于高原胃肠道疾病的诊治。多数研究结果表明,高原缺氧环境下肠黏膜的损伤可能与交感神经兴奋、遗传、氧自由基生成、自噬、微生态失衡等因素有关,以下就此进行概述。     

Helminthic therapy: improving mucosal barrier function

The epidemiology of autoimmune diseases and helminth infections led to suggestions that helminths could improve inflammatory conditions, which was then tested using animal models. This has translated to clinical investigations aimed at the safe and controlled reintroduction of helminthic exposure to patients suffering from autoimmune diseases (so-called 'helminthic therapy') in an effort to mitigate the inflammatory response. In this review, we summarize the results of recent clinical trials of helminthic therapy, with particular attention to mechanisms of action. Whereas previous reviews have emphasized immune regulatory mechanisms activated by helminths, we propose that enhancement of mucosal barrier function may have an equally important role in improving conditions of inflammatory bowel diseases.     

发酵乳对脓毒症患者肠黏膜屏障功能的影响

观察发酵乳对脓毒症患者肠黏膜屏障功能及炎症指标的影响。

选取60例确诊为脓毒症的患者, 随机分成对照组和发酵乳组, 每组各30例。对照组给予抗生素及营养支持治疗, 治疗组在常规综合治疗的基础上给予口服发酵乳治疗。在治疗前及治疗1周后分别检测并比较两组患者肠黏膜屏障功能、C-反应蛋白(CRP)、降钙素原(PCT)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)水平变化, 记录患者APACHEⅡ评分。采用SPSS 22.0软件进行数据统计。

治疗前两组患者的肠屏障功能、PCT和IL-6水平差异无统计学意义(P > 0.05)。治疗1周后, 发酵乳组血清内毒素(LPS)、血清二胺氧化酶(DAO)、D-乳酸、CRP、PCT、TNF-α、IL-6水平和APACHEⅡ评分较治疗前均显著降低(P < 0.05), 较对照组治疗后也降低(P < 0.05)。

脓毒症患者在常规综合治疗基础上加用发酵乳可改善肠粘膜屏障功能, 减轻患者全身炎症反应。

     

Protective effect of dexmedetomidine on intestinal mucosal barrier function in rats after cardiopulmonary bypass

Cardiopulmonary bypass can result in damage to the intestines, leading to the occurrence of systemic inflammatory response syndrome. Dexmedetomidine is reported to confer anti-inflammatory properties. Here, the purpose of this study is to investigate the effect of dexmedetomidine on the intestinal mucosa barrier damage in a rat model of cardiopulmonary bypass. It was observed that cardiopulmonary bypass greatly decreased the levels of hemodynamic parameters than SHAM group, whereas dexmedetomidine pretreatment in a cardiopulmonary bypass model rat prevented this reduction. Also, it showed that compared with control animals, cardiopulmonary bypass caused obvious mucosal damage, which was attenuated in dexmedetomidine + cardiopulmonary bypass group. The above findings were in line with that of dexmedetomidine pretreatment, which increased the expression of tight junction proteins, but it decreased the levels of DAO, D-LA, FABP2, and endotoxin. Moreover, the results demonstrated that due to pre-administration of dexmedetomidine, the level of pro-inflammatory factors was decreased, while the level of anti-inflammatory cytokine was increased. Also, it showed that dexmedetomidine suppressed TLR4/JAK2/STAT3 pathway that was activated by cardiopulmonary bypass. Together, these results revealed that dexmedetomidine pretreatment relieves intestinal microcirculation, attenuates intestinal damage, and inhibits the inflammatory response of cardiopulmonary bypass model rats, demonstrating that in CPB-induced damage of intestinal mucosal barrier function, dexmedetomidine pretreatment plays a protective role by inactivating TLR4/JAK2/STAT3-mediated inflammatory pathway.     

布拉酵母对小儿重症肺炎患儿肠黏膜屏障功能的影响

目的 探讨布拉酵母对小儿重症肺炎患儿肠黏膜屏障功能的影响。方法 将90例重症肺炎患儿按随机数字表分为对照组和观察组各45例。对照组患儿采用常规治疗,观察组患儿在常规治疗的同时加用布拉酵母治疗1周。比较两组患儿治疗前后血浆Ｄ-乳酸及肠型脂肪酸结合蛋白变化情况、胃肠功能障碍及腹泻发生率以及患儿不良反应。结果 治疗1周后,两组患儿血浆D-乳酸和肠型脂肪酸结合蛋白水平均低于治疗前（均P<0.01）,且不同时间点观察组指标水平下降幅度大于对照组（均P<0.01）。观察组患儿胃肠功能障碍发生率为6.7％、对照组为22.2％;观察组患儿腹泻发生率为15.6%,对照组为33.3%,二者比较差异均有统计学意义（均P<0.05）。观察组患儿无药物不良反应发生。结论 布拉酵母对重症肺炎患儿肠黏膜屏障具有保护作用,能减少胃肠功能障碍及腹泻发生率。     

参麦注射液对严重烫伤大鼠肠道屏障功能的保护作用

目的:探索参麦注射液对30% Ⅲ°烫伤早期肠道屏障功能的保护作用,为参麦注射液防治肠源性感染提供实验依据。方法:Wistar大鼠60只,随机分为正常对照组、模型对照组,地塞米松5 mg/kg组、参麦注射液5、10、15 mg/kg组,每组10只,使用烫伤仪建立30% Ⅲ°烫伤动物模型,立即腹腔注射相应的药物,每天1次。烫伤72 h后,检测肝脏、脾脏、肠系膜淋巴结细菌移位量、血浆内毒素、二胺氧化酶(DAO)、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)水平和肠粘膜分泌型免疫球蛋白A(sIgA)的水平。结果:与正常对照组比较,模型组肝脏、脾脏、肠系膜淋巴结细菌移位量,血浆内毒素、DAO、TNF-α及 IL-6和肠黏膜sIgA水平明显升高(P＜0.01);与模型组比较,地塞米松组和参麦注射液5、10、15 mg/kg组肝脏、脾脏、肠系膜淋巴结细菌移位量,血浆内毒素、DAO、TNF-α及 IL-6和肠黏膜sIgA水平明显降低(P＜0.05或P＜0.01)。结论:参麦注射液可减轻严重烫伤引起的肠粘膜损伤,效果与地塞米松相当,高剂量组效果更好。     

发酵乳对肝硬化失代偿期患者肠黏膜屏障功能的影响

观察发酵乳在改善肝硬化失代偿期患者肠黏膜屏障功能、肝功能及提高患者生活质量方面的作用。

选择我院78例确诊为肝硬化失代偿期的患者,随机分成对照组和发酵乳组,其中对照组42例,发酵乳组36例。对照组患者给予常规综合治疗,发酵乳组在常规综合治疗的基础上给予口服发酵乳治疗,在治疗前及治疗4周后分别检测并比较两组患者肠黏膜屏障功能、血清白蛋白、血浆氨水平及慢性肝病问卷评分（CLDQ）的变化。

治疗前两组患者肠屏障功能、血清白蛋白、氨水平及CLDQ评分差异无统计学意义（均P＞0.05）。治疗4周后,发酵乳组患者血清内毒素、血清二胺氧化酶、D-乳酸及血浆氨水平较治疗前显著降低,较对照组治疗后亦降低（均P＜0.05）。发酵乳组患者血清白蛋白水平及部分CLDQ评分较治疗前显著升高,较对照组治疗后亦升高（均P＜0.05）。

在常规综合治疗的基础上加用发酵乳可调节肝硬化失代偿期患者肠道菌群,改善肠黏膜屏障功能,从而保护肝脏功能,提高患者生活质量。

     

常乐康对乙肝肝硬化患者肠道菌群和肠道黏膜屏障功能的影响

目的探讨常乐康对乙肝肝硬化患者肠道菌群及肠道黏膜屏障功能的影响。方法收集乙肝肝硬化代偿期患者87例,其中治疗组48例,对照组39例。所有患者给予相同的常规护肝对症治疗,其中治疗组加用常乐康治疗8周。治疗结束后观察患者肠道菌群、肠道黏膜屏障功能和系统性炎症反应的改善情况。结果常乐康治疗后,患者肠道菌群中梭菌属I簇和XI簇及双歧杆菌属细菌数量显著升高,而肠杆菌科细菌及肠球菌属细菌数量显著降低;患者血清D-乳酸,内毒素(LPS)和二胺氧化酶(DAO)的水平显著下降,血清中促炎因子TNF-α和IFN-γ水平显著下降,而抗炎因子IL-10水平显著上升。结论常乐康可显著改善乙肝肝硬化患者肠道菌群组成和肠道黏膜屏障功能,有效减轻系统性炎症反应,可作为阻止乙肝肝硬化病情进展的有效辅助治疗方法。     

地衣芽胞杆菌BL63516对抗生素诱导的菌群紊乱小鼠肠黏膜屏障功能的影响

目的 探索地衣芽胞杆菌BL63516对肠道菌群和肠黏膜屏障功能调节的效果和可能机制,为临床疾病的治疗提供新思路。方法 采用健康清洁级雄性BALB/C小鼠30只构建动物模型,将小鼠分为3组（每组10只）,分别为对照组（CON组）、头孢曲松钠灌胃组（CS组）和地衣芽胞杆菌BL63516治疗组（BL组）,除CON组外其余两组小鼠给予300 mg/mL头孢曲松钠0.2 mL,2次/d灌服8 d,短期大量服用抗生素以建立肠道菌群紊乱模型。第9天起BL组小鼠给予地衣芽胞杆菌干预连续8 d。第17天摘眼球处死小鼠,取血、结肠、粪便样本。ELISA方法检测小鼠血清及肝脏组织中的细胞因子及LPS水平。PCR-变性梯度凝胶电泳方法及16S rRNA高通量测序测定小鼠肠道菌群结构。结果 地衣芽胞杆菌干预后小鼠血清LPS水平较模型组显著降低,屏障功能改善。且地衣芽胞杆菌治疗后BL组肠道菌群丰富度和多样性显著升高,菌群结构有所改变。结论 实验结果提示地衣芽胞杆菌BL63516可以有效改善抗生素所致的小鼠肠道菌群失调,对肠屏障功能有一定调节作用。     

双歧杆菌三联活菌肠溶胶囊 对重症肺炎患者肠黏膜屏障功能的保护作用

目的探讨双歧杆菌三联活菌肠溶胶囊对重症肺炎患者肠黏膜屏障功能的保护作用。方法选取重症肺炎患者66例,随机分为观察组（n=33例）和对照组（n=33例）。两组患者均予以吸氧、抗感染、抗休克和营养支持等常规治疗,必要时行机械通气或血管活性药物。观察组患者加用双歧杆菌三联活菌肠溶胶囊420 mg,3次/d,温水服用或水化后自鼻饲注入。观察两组患者治疗前和治疗14 d后内毒素、二胺氧化酶（DAO）和D-乳酸水平的变化,并比较其临床疗效。结果治疗14 d后,两组患者血清内毒素、DAO和D-乳酸水平均较前明显下降（P〈0.01或P〈0.05）,且观察组下降值明显大于对照组（P〈0.05）;同时观察组患者的临床总有效率明显高于对照组（χ2=3.88,P〈0.05）。结论双歧杆菌三联活菌肠溶胶囊辅助治疗重症肺炎患者具有较好的疗效,能明显降低血清内毒素、DAO和D-乳酸水平,减轻患者内毒素血症和肠黏膜通透性,保护患者肠黏膜屏障功能。     

短链脂肪酸对肠黏膜屏障的影响

肠黏膜屏障具有将致病性抗原等肠内物质与内环境隔离的功能,以维持内环境的相对稳定和机体的正常生命活动。其功能的维持依赖于人肠黏膜上皮细胞、肠道内正常菌群、肠道内分泌物和肠相关免疫细胞之间的功能协调,而其功能的发挥又受体内许多信号分子的影响。短链脂肪酸（short-chain fatty acids,SCFAs）就是其中一种重要的信号分子。SCFAs是肠道菌群的主要代谢产物之一,是肠道菌群与宿主代谢相互作用的媒介。宿主体内的SCFAs主要来自肠道菌群对膳食纤维的酵解,越来越多的研究证实,SCFAs不仅可以被肠道菌群利用,还可调节肠黏膜屏障及多种组织器官的代谢。本文主要就SCFAs对肠黏膜屏障的影响进行综述。

     

骶神经电刺激对急性脊髓损伤大鼠肠黏膜免疫屏障功能的影响

目的:观察骶神经根电刺激对急性完全性脊髓损伤大鼠肠黏膜免疫屏障功能的影响。方法:56只Wistar大鼠分为正常组(SG=8只)、脊髓损伤组(CG=24只)和骶神经电刺激组(EG=24只)。CG、EG (分别设24、48和72 h组,8只/组)。CG、EG大鼠均于全麻下用Fehlings法98 g动脉瘤夹横行钳夹行脊髓损伤并植入骶神经刺激电于右侧骶3神经孔。CG不进行干预,EG行骶神经电刺激。刺激参数:电压4 V,波宽210μs,频率15 Hz,刺激10s,间歇20 s。每次持续10 min,间歇10 min,共2 h。早8:00-10:00,晚6:00-8:00两次。分组采集标本,进行HE染色光镜、透射电镜组织学观察、Western blot方法检测组织锌指蛋白A20、NOD2和CD68蛋白表达量。结果:(1)肠道形态学观察:光镜和电镜观察脊髓损伤后黏膜结构破坏明显,肠腔细菌和杂质进入破损的肠黏膜上皮细胞、M细胞和经细胞间连接缝隙进入黏膜下,引起局部炎症反应;经电刺激后均有了很大程度改善。(2)锌指蛋白A20:与SG相比,CG各小组A20表达均明显降低(P<0.01);与SG、C...     

双歧杆菌三联活菌胶囊对化疗相关性腹泻患者肠黏膜屏障功能的保护作用

目的探讨双歧杆菌三联活菌胶囊对化疗相关性腹泻患者肠黏膜屏障功能的保护作用。方法选取78例化疗相关性腹泻患者,采用随机数字表将患者分为观察组（n=39例）和对照组（n=39例）。两组患者均常规予以补液,维持水电解质平衡及口服思密达3g,3次／d。观察组患者在此基础上加用双歧杆菌三联活菌胶囊420mg,3次／d。对照组除不使用双歧杆菌三联活菌胶囊外余治疗同观察组。观察两组患者治疗前和治疗3d后血清内毒素和和D-乳酸水平的变化,并比较其临床效果。结果治疗3d后,两组患者内毒素和和D-乳酸水平均有明显下降（P〈0．05或P〈0．01）,且观察组下降值明显大于对照组（P〈0．05）;同时观察组患者临床总有效率为92．31％,明显优于对照组的74．36％（x^2=4．52,P〈0．05）。结论双歧杆菌三联活菌胶囊治疗化疗相关性腹泻具有较好的临床效果,其作用机制可能是通过降低血清内毒素和D-乳酸水平,保护和改善改善肠黏膜屏障功能,从而恢复患者的肠功能。     

Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats

Background  

Glutathione, the main antioxidant of intestinal epithelial cells, is suggested to play an important role in gut barrier function and prevention of inflammation-related oxidative damage as induced by acute bacterial infection. Most studies on intestinal glutathione focus on oxidative stress reduction without considering functional disease outcome. Our aim was to determine whether depletion or maintenance of intestinal glutathione changes susceptibility of rats to Salmonella infection and associated inflammation.     

术前补充益生菌对肠道手术患者术后肠道菌群及肠黏膜屏障功能的影响

目的 探讨术前补充益生菌对肠道手术患者术后肠道菌群及肠黏膜屏障功能的影响。方法 选取肠道手术患者86例,随机分为观察组和对照组各43例。两组患者术前予以常规肠道准备,术后给予等营养支持及抗生素等治疗。观察组患者术前7 d开始加用双歧杆菌三联活菌胶囊温水口服,630 mg/次,2次/d。观察两组患者术后肠道功能恢复及感染并发症情况,并比较术前7 d及术后首次自然排便时两组患者肠道菌群数量及肠黏膜屏障指标变化。结果 观察组患者术后肠鸣音恢复时间、肛门排气时间、排便时间均短于对照组（均P0.05）。术后首次自然排便时两组患者血清D-乳酸和DAO水平高于术前7 d时（P<0.05）,且观察组患者术后D-乳酸和DAO水平低于对照组（P<0.05）。结论 肠道手术患者术前补充益生菌可调节肠道菌群,降低肠黏膜通透性,改善其肠道功能,减少术后感染并发症的发生率。     

Dietary genistein supplementation improves intestinal mucosal barrier function in Escherichia coli O78-challenged broilers

Genistein has multiple biological activities in both humans and animals. However, a protective effect of genistein on Escherichia coli (E. coli)-induced intestinal mucosal barrier dysfunction remains unknown. In the present study, a total of 288 1-day-old male Arbor Acre broilers fed a corn-soybean basal diet unsupplemented or supplemented with 20 mg genistein/kg diet were subjected to E. coli serotype O78 (10⁸ cfu per bird) infection or equal volume of sodium chloride at 19 days of age. Sera and tissue samples were collected 2 days after E. coli infection. Growth performance, index of immune-related organs, intestinal barrier permeability, protein level of inflammatory cytokines, sIgA, tight junction protein, and mRNA level of apoptotic genes in jejunum were determined. Mortality rate at 7 days post infection was recorded. The results showed that E. coli challenge led to a reduced average daily gain, a decreased thymus index, and bursal index in broilers, an increase of fluorescein isothiocyanate (FITC)-dextran in serum, and a decreased sIgA in jejunum. These effects were abrogated by genistein administration. Western blot results showed that E. coli infection led to increased protein level of claudin-1 and zonula occludens (ZO)-1, which was largely abolished by genistein. Moreover, E. coli infection resulted increased protein level of TNF-α and IL-6, enhanced mRNA level of Bax and caspase-3, as well as decreased mRNA level of Bcl-2 were abrogated by genistein in jujunum of broilers. In conclusion, the results indicate that genistein supplementation improves intestinal mucosal barrier function which is associated with a regulatory effect on tight junction proteins, sIgA, apoptosis, and secretion of inflammatory cytokines in jejunum of E. coli-challenged broilers.     

双歧三联活菌胶囊对急性胰腺炎患者肠黏膜屏障功能的保护作用

目的探讨双歧三联活菌胶囊对急性胰腺炎患者肠黏膜屏障功能的保护作用。方法选取急性胰腺炎患者66例,随机分为观察组和对照组。两组患者均予以禁食水、持续胃肠减压、解痉镇痛、抗感染、抑制胃酸分泌、生长抑素、改善局部微循环和保持水电解质酸碱平衡等常规治疗。观察组患者加用双歧杆菌三联活菌胶囊420mg水化后自胃管灌注,夹管1．5h,3次／d,连用7d。观察两组患者的治疗前后肠黏膜屏障功能的变化情况,并比较其临床疗效。结果治疗7d后,两组患者血清内毒素、TNF—α和D-乳酸水平均有明显下降（P〈0．05或P〈0．01）,且观察组下降值比对照组更明显（P〈0．05）;同时观察组患者临床总有效率为93．94％,明显高于对照组的75．76％（χ2=4．24,P〈0．05）。结论双歧杆菌三联活菌胶囊治疗急性胰腺炎效果较好,能降低血清内毒素、TNF-α和D-乳酸水平,对患者肠黏膜屏障功能具有良好的保护作用。